Monopar Therapeutics Gains 'Buy' Rating Amid Promising Licensing Deal With AstraZeneca and Strong Growth Prospects
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $87
AstraZeneca's Strategic Positioning and Datroway Approval Drive Buy Rating Amidst Evolving Breast Cancer Treatment Landscape
Analysts' Opinions Are Mixed on These Healthcare Stocks: AstraZeneca (GB:AZN), CSL (OtherCMXHF) and UCB SA (GB:0NZT)
AstraZeneca (AZN) Gets a Buy From Goldman Sachs
BofA Securities Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $91.7
Bank of America Securities Remains a Buy on AstraZeneca (AZN)
AstraZeneca's Strong Growth Forecasts and Strategic Position Justify Buy Rating Despite Market Concerns
Kepler Capital Remains a Hold on AstraZeneca (AZN)
J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)
AstraZeneca (AZN) Receives a Buy From Barclays
AstraZeneca (AZN) Receives a Buy From Goldman Sachs
AstraZeneca (AZN) Gets a Buy From TD Cowen
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
AstraZeneca (AZN) Gets a Buy From J.P. Morgan
AstraZeneca (AZN) Gets a Hold From Kepler Capital
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95
TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)
AstraZeneca (AZN) Receives a Hold From Jefferies
Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)